PHILADELPHIA, Aug. 4 /PRNewswire-FirstCall/ -- eResearchTechnology,
Inc. (eRT), (Nasdaq: ERES), a leading provider of centralized ECG and
eClinical technology, ePRO and other services to the pharmaceutical,
biotechnology, medical device and related industries, announced today
results for the second quarter and six-month period ended June 30, 2008.

Financial highlights for the second quarter of 2008 were:

-- Record quarterly net revenues of $35.5 million, a 43.4% increase
from the second quarter of 2007;

-- Diluted net income per share of $0.13, a 62.5% increase from the
second quarter of 2007;

-- Gross margin of $20.2 million for a gross margin percentage of
57.0%, a 310 basis point increase from the second quarter of 2007. The
gross margin included the impact of the operating results of CCSS and the
integration of CCSS into eRT. CCSS generated net revenues of $3.0 million
while incurring costs of revenue of $2.4 million;

-- Operating income of $10.8 million, a 72.2% increase from the second
quarter of 2007. Operating income margin percentage was 30.3%, a 500 basis
point increase from the second quarter of 2007. Operating income included a
loss of $0.3 million from the operations of CCSS and the integration of
CCSS into eRT;

-- New bookings of $49.0 million compared to $34.5 million for the
second quarter of 2007, an increase of 42.0%;

-- New bookings included a record 15 new Thorough ECG study agreements,
valued at an average of slightly greater than $900,000 each;

-- The backlog was a record $157.9 million, an increase of $6.5 million
from March 31, 2008.

-- The book-to-bill ratio was 1.4 in the second quarter of 2008, the
same as in the second quarter of 2007; and

-- eRT ended the second quarter with $55.9 million in cash, cash
equivalents and investments, an increase of $7.0 million from $48.9 million
at March 31, 2008. For the three months ended June 30, 2008, net cash
provided by operating activities was $10.4 million.

Other recent highlights:

-- eRT appointed Keith Schneck as its new Chief Financial Officer in
July 2008; Mr. Schneck has extensive public company experience as the CFO
for Neoware, Inc. and Integrated Circuit Systems;

-- The cancellation rate was an annualized 18.1% as compared to an
annualized cancellation rate of 17.6% in the second quarter of 2007;

-- Reflecting our growth, we are moving our corporate headquarters (and
US-based core lab) in Philadelphia to a larger facility, also in
Philadelphia, by the end of 2008; and

-- eRT appointed Michael DeMane to the Board of Directors in July 2008.
Mr. DeMane was previously Chief Operating Officer of Medtronic, Inc. and
served as Senior Vice President and President Europe, Canada, Latin America
and Emerging Markets. Mr. DeMane brings a wealth of international
operations and marketing experience to the Board.

"We are very pleased with the second quarter results where we saw
record quarterly revenue, ECG transactions, backlog and very strong
bookings for eRT," commented Dr. Michael McKelvey, President and CEO of
eRT. "Our services revenue grew by 55.9%, driven by outstanding growth in
our core cardiac safety business. Bookings were strong, especially for
Thorough QT studies. In comparison to the first quarter of 2008, margins
increased in all three revenue categories -- services, site support, and
licenses. Net income was $6.7 million, an increase of 60.9% from $4.1
million for the second quarter of 2007. The second quarter results again
demonstrated the leverage in our business model as evidenced by expanding
gross margins and net income growth."

For the six months ended June 30, 2008, the Company reported revenues
of $69.1 million compared to $45.8 million for the six months ended June
30, 2007, an increase of 50.9%. eRT reported net income of $12.4 million,
or $0.24 per diluted share, for the six months ended June 30, 2008 compared
to net income of $6.4 million, or $0.12 per diluted share, for the six
months ended June 30, 2007.

The Company's gross margin percentage for the six months ended June 30,
2008 was 54.8% compared to 51.0% for the six months ended June 30, 2007.
Operating income margin for the six months ended June 30, 2008 was 27.8%
compared to 20.4% for the six months ended June 30, 2007. The Company's tax
rate was 37.7% for the six months ended June 30, 2008 compared to 39.0% for
the six months ended June 30, 2007. For the six months ended June 30, 2008,
cash provided by operating activities was $18.0 million.

"We continue to execute very well on our projects. The integration of
the CCSS acquisition is approximately 3 months ahead of schedule. We are
very fortunate to hire someone of the caliber of Keith Schneck as our new
CFO. We believe that he will make a strong impact on our business. Our
pipeline of new opportunities is strong, reflecting the continued emphasis
on cardiac safety and eRT's reputation for quality, medical and scientific
leadership, project execution and technology innovation," continued Dr.
McKelvey. "The pricing environment continues to be stable. We continue to
see expanded opportunities with all of our CRO key partnerships and Phase I
units. While there are many areas in which we need to continue to improve,
the first half of the year has been an excellent start to the year."

2008 Guidance

The Company issued guidance for the third quarter of 2008 and for the
full year 2008. eRT expects to report revenues of between $33.0 million and
$35.0 million, reflecting a normal slowdown due to summer vacations which
typically reduces study activity, and diluted net income per share of
between $0.10 to $0.12 for the third quarter ending September 30, 2008. For
the full year 2008, the Company is confirming its previously issued
guidance for revenue of between $133.0 million and $140.0 million and
increasing the lower end of its guidance for diluted net income per share
to between $0.46 to $0.49; previously issued guidance for diluted net
income per share was between $0.44 to $0.49.

Dr. McKelvey and Keith Schneck, the Company's Chief Financial Officer,
will hold a conference call to discuss these results. The conference call
will take place at 5:00 p.m. EDT on August 4, 2008. Interested participants
should call 800-659-2032 when calling within the United States or
617-614-2712 when calling internationally. Please use pass code 98614709.
There will be a playback available until August 11, 2008. To listen to the
playback, please call 888-286-8010 when calling within the United States or
617-801-6888 when calling internationally. Please use pass code 80358836
for the replay.

Based in Philadelphia, PA, eResearchTechnology, Inc.
(http://www.eRT.com) is a provider of technology and services to the
pharmaceutical, biotechnology and medical device industries on a global
basis. The Company is a market leader in providing centralized
core-diagnostic electrocardiographic (ECG) technology and services to
evaluate cardiac safety in clinical development. The Company is also a
leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection,
analysis, and distribution of clinical data in all phases of clinical
development.

Statements included in this release may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Such statements, including, but not limited to, 2008 financial
guidance, involve a number of risks and uncertainties such as the Company's
ability to obtain new contracts and accurately estimate net revenues due to
uncertain regulatory guidance, variability in size, scope and duration of
projects, and internal issues at the sponsoring client, integration of
acquisitions, competitive factors, technological development, and market
demand. As a result, actual results may differ materially from any
financial outlooks stated herein. Further information on potential factors
that could affect the Company's financial results can be found in the
Company's Reports on Form 10-K and 10-Q filed with the Securities and
Exchange Commission. The Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future events, or otherwise.

(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events company, ... today. The bold new look is part of a transformation to increase awareness, ... significant growth period. , It will also expand its service offering from its signature ...

(Date:10/9/2017)... , ... October 09, 2017 , ... The award-winning American ... broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , ... faced with the challenge of how to continue to feed a growing nation. At ...

(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...

(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...

(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...